Targeting strategies for human immunodeficiency virus: A combinatorial approach

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 236-254

  Saxena, S K ^a   Gupta, A ^b   Bhagyashree, K ^b   Saxena, R ^a   Arora, N ^a   Banerjee, A K ^c   Tripathi, A K ^d   Chandrasekar, M J N ^b   Gandhi, N ^e   Nair, M P N ^e  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b JSS COLLEGE OF PHARMACY   (India)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^d KING GEORGE'S MEDICAL UNIVERSITY   (India)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

And inhibitors; Carbohydrate binding proteins; Griffithsin; HIV; Host cellular target; Integrase; Lentivirus; Life cycle; Nucleoside; Protease; Reverse transcriptase; Synthesis; Treatment

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ABACAVIR; AMPRENAVIR; ANCRIVIROC; APLAVIROC; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANONISE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; LAMIVUDINE; MARAVIROC; NBD 556; NBD 557; NEVIRAPINE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CELL FUSION; DISEASE COURSE; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FUSION GENE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; NONHUMAN; QT PROLONGATION; RECEPTOR BINDING; REVIEW; SEXUAL BEHAVIOR; SURVIVAL; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION;

EID: 84863393034     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511209030236     Document Type: Review

References (115)

1. Campbell, R. S. F.; Robinson, W. F. The Comparative Pathology of the Lentiviruses. J. Comp. Path., 1998, 119, 333-395.
2. Pepin, J.; Morgan, G.; Dunn, D.; Gevao, S.; Mendy, M.; Gaye, I.; Scollen, N.; Tedder, R.; Whittle, H. HIV-2-induced immunosuppression among asymptomatic west African prostitutes: Evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS, 1991, 5, 1165-1172.
3. Pantaleo, G.; Graziosi, C.; Fauci, A.S. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N. Engl. J. Med., 1993, 328, 327-335.
4. Fauci, A.S.; Lane, H.C. In: Harrison's principles of internal medicine; Kasper, D.L., et al.; Ed.; McGraw-Hill: New York, 2005; pp. 1076-1139.
5. Markovitz, D.M. Infection with the human immunodeficiency virus type 2. Ann. Intern. Med., 1993, 118, 211-218.
6. Rosenberg, Z.F.; Fauci, A.S. The immunopathogenesis of HIV infection. Adv. Immunol., 1989, 47, 377-431.
7. Levy, J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev., 1993, 57, 183-289.
8. Tilton, J. C.; Doms, R. W. Entry inhibitors in the treatment of HIV-1 infection. Antivir. Res., 2010, 85, 91-100.
9. Sinoussi, F. B. HIV as the cause of AIDS. Lancet, 1996, 348, 31-35.
10. Rosenberg, Z.F.; Fauci, A.S. The immunopathogenesis of HIV infection. Adv. Immunol., 1989, 47, 377-431.
11. Cooper, D.A.; Tindall, B.; Wilson, E.J.; Imrie, A.A.; Penny, R. Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. J. Infect. Dis., 1988, 157, 889-896.
12. Willey, R.L.; Maldarelli, F.; Martin, M.A.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J. Virol., 1992, 66, 226-234.
13. Willey, R.L.; Maldarelli, F.; Martin, M.A.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol., 1992, 66, 7193-7200.
14. Anderson, S.; Shugars, D.C.; Swanstrom, R.; Garcia, J.V. Nef from primary isolates of human immunodeficiency virus type 1 suppresses surface CD4 expression in human and mouse T cells. J. Virol., 1993, 67, 4923-4931.
15. Benson, R.E.; Sanfridson, A.; Ottinger, J.S.; Doyle, C.; Cullen, B.R. Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J. Exp. Med., 1993, 177, 1561-1566.
16. Chen, M.Y.; Maldarelli, F.; Karczewski, M.K.; Willey, R.L.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: The cytoplasmic domain of CD4 contributes to Vpu sensitivity. J. Virol., 1993, 67, 3877-3884.
17. Garcia, J.V.; Alfano, J.; Miller, A.D. The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4. J. Virol., 1993, 67, 1511-1516.
18. Mariani, R.; Skowronski, J. CD4 downregulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals. Proc. Natl. Acad. Sci., 1993, 90, 5549-5553.
19. Rosenberg, Z.F.; Fauci, A.S. The immunopathogenesis of HIV infection. Adv. Immunol., 1989, 47, 377-431.
20. Rosenberg, Z.F.; Fauci, A.S. Immunopathogenesis of HIV infection. In AIDS: Etiology, diagnosis, treatment and prevention, 3rd edition (ed. V.T. DeVita, Jr. et al), 1992, pp. 61-76. J.B. Lippincott, Philadelphia.
21. Haase, A.T. Pathogenesis of lentivirus infections. Nature, 1986, 322, 130-136.
22. Botarelli, P.; Houlden, B.A.; Haigwood, N.L.; Servis, C.; Montagna, D.; Abrignani, S. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J. Immunol., 1991, 147, 3128-3132.
23. Benjouad, A.; Gluckman, J.C.; Rochat, H.; Montagnier, L.; Bahraoui, E. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J. Virol., 1992, 66, 2473-2483.
24. Moore, J.P.; Ho, D.D. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol., 1993, 67, 863-875.
25. Kirchhoff, F.; Greenough, T.C.; Brettler, D.B.; Sullivan, J.L.; Desrosiers, R.C. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med., 1995, 332, 228-232.
26. Deacon, N.J. et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science, 1995, 270, 988-991.
27. Kestler, H.W. et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell, 1991, 65, 651-662.
28. Daniel, M.D.; Kirchhoff, F.; Czajak, S.C.; Sehgal, P.K.; Desrosiers, R.C. Protective effects of a live attentuated SIV vaccine with a deletion in the nef gene. Science, 1992, 258, 1938-1941.
29. Luo, T.; Garcia, J.V. The association of nef with a cellular serine/threonine kinase and its enhancement of infectivity are viral isolate dependent. J. Virol., 1996, 70, 6493-6496.
30. Wiskerchen, M.; Chang-Mayer C. HIV-1 nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis. Virology, 1996, 224, 292-301.
31. Fultz, P.N. Replication of an acutely lethal simian immunodeficiency virus activates and induces proliferation of lymphocytes. J. Virol., 1991, 65, 4902-4909.
32. Du, Z. et al. Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys. Cell, 1995, 82, 665-674.
33. + lymphocyte counts: Immunologic and virologic characteristics. J. Infect. Dis., 1991, 163, 959-965.
34. Cheng-Mayer, C.; Seto, D.; Tateno, M.; Levy, J.A. Biologic features of HIV-1 that correlate with virulence in the host. Science, 1988, 240, 80-82.
35. + cell anti-HIV activity: Nonlytic suppression of virus replication. AIDS Res. Hum. Retroviruses, 1992, 8, 1039-1050.
36. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science, 1996, 273, 1856-1862.
37. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med., 1996, 2, 1240-1243.
38. Wang, W.K. et al. Pattern of gp120 sequence divergence linked to a lack of clinical progression in human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci., 1996, 93, 6693-6697.
39. Wolinsky, S.M. et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science, 1996, 272, 537-542.
40. Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Disc., 2007, 6, 959-966.
41. Sheehy, A.M.; Gaddis, N.C.; Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 2002, 418, 646-650.
42. Bishop, K. N.; Holmes, R. K.; Sheehy, A. M.; Malim, M. H. APOBEC-mediated editing of viral RNA. Science, 2004, 305, 645-649.
43. Vandekerckhove, L.; Christ, F.; Van Maele, B.; De Rijck, J.; Gijsbers, R.; Vanden Haute, C.; Witvrouw, M.; Debyser, Z. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J. Virol., 2006, 80, 1886-1896.
44. Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature, 2004, 427, 848-853.
45. Stremlau, M.; Perron, M.; Lee, M.; Li, Y.; Song, B.; Javanbakht, H.; Diaz-Griffero, F.; Anderson, D.J.; Sundquist, W.I.; Sodroski, J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 5514-5519.
46. Neil, S.J.; Zang, T.; Bieniasz, P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 2008, 451, 425-430.
47. Van Damme, N.; Goff, D.; Katsura, C.; Jorgenson, R.L.; Mitchell, R.; Johnson, M.C.; Stephens, E.B.; Guatelli, J. The interferoninduced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Host Cell Microbe, 2008, 3, 242-252.
48. Rosenberg, Z.F.; Fauci, A.S. The immunopathogenesis of HIV infection. Adv. Immunol., 1989, 47, 377-431.
49. Levy, J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev., 1993, 57, 183-289.
50. Chesebro, B.; Buller, R.; Portis, J.; Wehrly, K. Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J. Virol., 1990, 64, 215-221.
51. Dalgleish, A.G.; Beverley, P.C.; Clapham, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 1984, 312, 763-767.
52. Berger, E.A.; Murphy, P.M.; Farber, J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol., 1999, 17, 657-700.
53. Lobritz, M. A.; Ratcliff, A. N.; Arts, E. J. HIV-1 Entry, Inhibitors, and Resistance. Viruses, 2010, 2, 1069-1105.
54. Miyauchi, K.; Kim, Y.; Latinovic, O.; Morozov, V.; Melikyan, G.B. HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes. Cell, 2009, 137, 433-444.
55. Cherepanov, P.; Ambrosio, A.L.; Rahman, S.; Ellenberger, T.; Engelman, A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 17308-17313.
56. Cherepanov, P.; Maertens, G.; Proost, P.; Devreese, B.; Van Beeumen, J.; Engelborghs, Y.; De Clercq, E.; Debyser, Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem., 2003, 278, 372-381.
57. Greene, W. C.; Debyser, Z.; Ikeda, Y.; Freed, E. O.; Stephens, E.; Yonemoto, W.; Buckheit, R. W.; Este, J. A; Cihlar, T. Novel targets for HIV therapy. Antivir. Res., 2008, 80, 251-265.
58. Wu, Y. The second chance story of HIV-1 DNA: Unintegrated? Not a problem! Retrovir., 2008, 5, 61.
59. Poon, B; Chen, I. S. Y. Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J. Virol., 2003, 77(7), 3962-3972.
60. Gelderblom, H. C.; Vatakis, D. N.; Burke, S. A.; Lawrie, S. D.; Bristol, G. C.; Levy, D. N. Viral complementation allows HIV-1 replication without integration. Retrovir., 2008, 5(60), 1-18.
61. Zdanowicz, M. M. The Pharmacology of HIV Drug Resistance. Am. J. Pharm. Edu., 2006, 70 (5), 1-9.
62. Liddament, M. T.; Brown, W. L.; Schumacher, A. J.; Harris, R. S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol., 2004, 14(15), 1385-1391.
63. Dang, Y.; Wang, X.; Esselman, W. J.; Zheng, Y. H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol., 2006, 80(21), 10522-10533.
64. Bourara, K.; Liegler, T. J.; Grant, R. M. Target Cell APOBEC3C Can Induce Limited G-to-A Mutation in HIV-1. PLoS Pathog., 2007, 3(10), e153.
65. Gabuzda, D.; Lawrence, K.; Langhoff, E.; Terwilliger, E.; Dorfman, T.; Haseltine, W.A.; Sodroski, J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol., 1992, 66, 6489-6495.
66. Sheehy, A.M.; Gaddis, N.C.; Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 2002, 418, 646-650.
67. Conticello, S.G.; Harris, R.S.; Neuberger, M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol., 2003, 13, 2009-2013.
68. Marin, M.; Rose, K.M.; Kozak, S.L.; Kabat, D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Med., 2003, 9, 1398-1403.
69. Stopak, K.; Noronha, C.D.; Yonemoto, W.; Greene, W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell, 2003, 12, 591-601.
70. Fujita, M.; Sakurai, A.; Yoshida, A.; Miyaura, M.; Koyama, A.H.; Sakai, K.; Adachi, A. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif. J. Virol., 2003, 77, 1626-1632.
71. Douaisi, M.; Dussart, S.; Courcoul, M.; Bessou, G.; Lerner, E.C.; Decroly, E.; Vigne, R. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosinephosphorylated APOBEC3G into vifdefective HIV-1 particles. Biochem. Biophys. Res. Commun., 2005, 329, 917-924.
72. Pillai, S. K.; Wong, J. K.; Barbour, J. D. Turning up the volume on mutational pressure: Is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovir., 2008, 5, N26.
73. Khrustalev V. V. HIV1 V3 loop hypermutability is enhanced by the guanine usage bias in the part of env gene coding for it. In Silico Biology., 2009, 9(4), 255-269.
74. Khrustalev V. V. Mutational pressure makes HIV1 gp120 linear Bcell epitopes shorter and may lead to their disappearance. Mol. Immunology, 2010, 47(7-8), 1635-1639.
75. Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5α restricts HIV-1 infection in old world monkeys. Nature, 2004, 427, 848-853.
76. Stremlau, M.; Perron, M.; Lee, M.; Li, Y.; Song, B.; Javanbakht, H.; Diaz-Griffero, F.; Anderson, D.J.; Sundquist, W.I.; Sodroski, J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 5514-5519.
77. Anderson, J.; Akkina, R. TRIM5αrh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. Mol. Ther., 2005, 12, 687-696.
78. Li, Y.; Li, X.; Stremlau, M.; Lee, M.; Sodroski, J. Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J. Virol., 2006, 80, 6738-6744.
79. Yap, M.W.; Nisole, S.; Stoye, J.P. A single amino acid change in the SPRY domain of human TRIM5α leads to HIV-1 restriction. Curr. Biol., 2005, 15, 73-78.
80. Asaoka, K.; Ikeda, K.; Hishinuma, T.; Horie-Inoue, K.; Takeda, S.; Inoue, S. A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem. Biophys. Res. Commun., 2005, 338, 1950-1956.
81. Sakuma, R.; Mael, A.A.; Ikeda, Y. Alpha interferon enhances TRIM5alpha mediated antiviral activities in human and rhesus monkey cells. J. Virol., 2007, 81, 10201-10206.
82. Sakuma, R.; Noser, J.A.; Ohmine, S.; Ikeda, Y. Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nature Med., 2007, 13, 631-635.
83. Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature, 2004, 427, 848-853.
84. Cohen, E.A.; Terwilliger, E.F.; Sodroski, J.G.; Haseltine, W.A. Identification of a protein encoded by the vpu gene of HIV-1. Nature, 1988, 334, 532-534.
85. Paul, M.; Jabbar, M.A. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpumediated ER degradation of CD4. Virology, 1997, 232, 207-216.
86. Fujita, K.; Omura, S.; Silver, J. Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors. J. Gen. Virol., 1997, 78, 619-625.
87. Gonzalez, M.E.; Carrasco, L. Viroporins. FEBS Lett., 2003, 552, 28-34.
88. Tilton, J. C.; Doms, R. W. Entry inhibitors in the treatment of HIV-1 infection. Antivir. Res., 2010, 85, 91-100.
89. Qadir, M. I.; Malik, S. A. HIV fusion inhibitors. Rev. Med. Virol., 2010, 20, 23-33.
90. Horwitz, J. P.; Chua, J.; Noel, M. Nucleosides. V. The Monomesylates of l-(2'-Deoxy-β-D-lyxofuranosyl)thymine. J. Org. Chem., 1964, 29, 2076-2078.
91. Available from: http://www.chm.bris.ac.uk/webprojects2002/levasseur/nrtis/nrtis4.htm (Accessed on October 15, 2010).
92. Mitsuya, H.; Weinhold, K.J.; Furman, P.A.; St. Clair, M.H.; Lehrman, S.N.; Gallo, R.C.; Bolognesi, D.P.; Berry, D.W.; Broder, S. 3'-Azido-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human Tlymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci, U.S.A., 1985, 82, 7096-7100.
93. Furman, P.A.; Fyfe, J.A.; St. Clair, M.H.; Weinhold, K.J.; Rideout, J.L.; Freeman, G.A.; Lehrman, S.N.; Bolognesi, D.P.; Broder, S.; Mitsuya, H. et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A, 1986, 83, 8333-8337.
94. Lavie, A.; Schlichting, I.; Vetter, I.R.; Konrad, M.; Reinstein, J.; Goody, R.S. The bottleneck in AZT activation. Nature Med., 1997, 3, 922-924.
95. Coates, J.A.V.; Mutton, I.M.; Penn, C.R.; Storer, R.; Williamson, C. Preparation of 1,3-oxathiolane nucleoside analogs and pharmaceutical compositions containing them. IAF Biochem InterNature Inc., WO 9,117,159, 1991.
96. Liotta, D.C.; Schinazi, R.F.; Choi, W.B. Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane. WO 9,214,743, 1992.
97. Yarchoan, R.; Mitsuya, H.; Thomas, R.V.; Pluda, J.M.; Hartman, N.R.; Perno, C.F.; Marczyk, K.S.; Allain, J.P.; Johns, D.G.; Broder, S. In vivo-Activity Against HIV and Favorable Toxicity Pro of 2',3'-Dideoxyinosine. Science, 1989, 245, 412-415.
98. Yarchoan, R.; Perno, C.F.; Thomas, R.V.; Klecker, R.W.; Allain, J.P.; Wills, R.J.; McAtee, N.; Fischl, M.S.; Dubinsky, R.; McNeely, M.C. et al. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet, 1988, 1, 76-81.
99. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.J.; Breslin, H.J.; Raeymaeckers, A.; Van Galder, J.; Woestenborghs, R.; Heykants, J. et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 1990, 343, 470-474.
100. Merluzzi, V.J.; Hargrave, K.D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J.C.; Shih, C.K.; Eckner, K.; Hattox, S.; Adams, J. et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science, 1990, 250, 1411-1413.
101. Kelly, T. A.; Patel, U. R. Directed Lithiation of 3-[(tert-Butoxycarbonyl)amino]-2-methoxypyridines: Synthetic Route to Nevirapine and Its 4-Substituted Derivatives. J. Org. Chem., 1995, 60, 1875-1877.
102. Pierce, M. E.; Parsons, R. L.; Jr. Radesca, L. A.; Lo, Y. S.; Silverman, S.; Moore, J. R.; Qamrul, I.; Choudhury, A.; Fortunak, J. M. D.; Nguyen, D.; Luo, C.; Morgan, S. J.; Davis, W. P.; Confalone, P. N. Practical Asymmetric Synthesis of Efavirenz (DMP 266), an HIV-1 Reverse Transcriptase Inhibitor. J. Org. Chem., 1998, 63, 8536-8543.
103. Romero, D.L.; Morge, R.A.; Biles, C.; Berrios-Pena, N.; May, P.D.; Palmer, J.R.; Johnson, P.D.; Smith, H.W.; Busso, M.; Tan, C.K. et al. Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. J. Med. Chem., 1994, 37, 999-1014.
104. Romero, D.L. et al. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogs and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)am ino]pyridinyl]piperazinemonomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem., 1993, 36, 1505-1508.
105. Tucker, T.J.; Lyle, T.A.; Wiscount, C.M.; Britcher, S.F.; Young, S.D.; Samders, W.M.; Lumma, W.C.; Goldmen, M.E.; O'Brien, J.A.; Ball, R.G. et al. Synthesis of a Series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. J. Med. Chem., 1994, 37, 2437-2444.
106. Evering, T. H.; Markowitz, M. HIV-1 Integrase Inhibitors. The PRN Notebook, 2008, 13, 1-9.
107. Luo, Z.G.; Tan, J.J.; Zeng, Y.; Wang, C.X.; Hu, M.L. Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: An overview. Mini-Rev. Med. Chem., 2010, 10(11), 1046-1057.
108. Shityakov, S.; Dandekar, T. Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric-shape similarity scoring function. Bioinformation, 2010, 4(7), 295-299.
109. Balzarini, J. Inhibition of HIV entry by carbohydrate-binding proteins. Antivir. Res., 2006, 71, 237-247.
110. Ziolkowska, N. E. et al. Domain-Swapped Structure of the Potent Antiviral Protein Griffithsin and Its Mode of Carbohydrate Binding. Structure, 2006, 14, 1127-1135.
111. Shityakov, S; Rethwilm, A; Dandekar, T. Structural and docking analysis of HIV-1 integrase and Transportin-SR2 interaction: Is this a more general and specific route for retroviral nuclear import and its regulation? Online J. Bioinformatics, 2010, 11(1), 19-33.
112. Tan, J.J.; Cong, X.J.; Hu, L.M.; Wang, C.X.; Jia, L.; Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov. Today, 2010, 15(5-6), 186-197.
113. Tindall, B.; Cooper, D.A. Primary HIV infection: Host responses and intervention strategies. AIDS, 1991, 5, 01-14.
114. Fauci, A.S.; Lane, H.C. In: Harrison's principles of internal medicine; Kasper, D.L., et al.; Ed.; McGraw-Hill: New York, 2005; pp. 1076-1139.
115. Lobritz, M. A.; Ratcliff, A. N.; Arts, E. J. HIV-1 Entry, Inhibitors, and Resistance. Viruses, 2010, 2, 1069-1105.